Lexeo Therapeutics to present new neurologic assessment data on LX2006 Friedreich ataxia gene therapy at MDS 2026

• Lexeo Therapeutics flagged an upcoming oral presentation on LX2006 gene therapy for Friedreich ataxia at MDS 2026 in Seoul.
• The update will include previously reported findings that suggested early stabilization or improvement in neurological function versus a matched natural-history cohort.
• New analyses are set to break out neurological subscores to sharpen the read-through on potential treatment impact beyond earlier cardiac observations.
• Data are scheduled for presentation on Oct. 7, 2026, positioning the program for closer investor scrutiny ahead of later-stage development decisions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexeo Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610010900PRIMZONEFULLFEED9837611) on October 01, 2026, and is solely responsible for the information contained therein.